Is Ozempic safe for weight loss?
Choosing medication to support weight loss is a big decision. It’s completely natural to want clear answers about safety and possible risks. Medicines like Ozempic and Wegovy have had a lot of media attention, and the information out there can feel mixed or confusing. To make a well-informed choice, it’s important to look at scientific evidence and individual medical assessment rather than headlines.
.svg)
Here’s a summary of what research shows about the safety of semaglutide, the active ingredient in Ozempic and Wegovy, what the known risks are, and how treatment is monitored to keep it as safe as possible.
Interest in semaglutide has grown quickly in recent years, both in type 2 diabetes care and obesity treatment. The medication has been studied in large clinical trials and is now widely used internationally, including in the UK. Like all medical treatment, it needs to be prescribed to the right person, at the right dose, with proper follow-up. Safety does not depend only on the medicine itself, but also on careful assessment, individual tailoring, and ongoing support from a doctor.
How does Ozempic work?
Ozempic contains semaglutide, a GLP-1 receptor agonist. It was originally developed to treat type 2 diabetes and is well studied in terms of both effectiveness and safety.
In large clinical trials, semaglutide has shown strong effects on blood sugar control and, at higher doses, significant weight loss. In the STEP programme, which looked at semaglutide in people living with obesity, participants lost on average around 15% of their body weight after about 68 weeks of treatment, alongside lifestyle support. Individual results vary depending on dose, starting weight, adherence, and lifestyle factors.
In cardiovascular outcome trials, semaglutide has also been shown to reduce the risk of serious heart events in people with type 2 diabetes and in people living with obesity who have established cardiovascular disease. This forms part of the overall risk–benefit assessment.
Semaglutide works by activating GLP-1 receptors. This affects appetite regulation, feelings of fullness, stomach emptying, and blood sugar control. For many people, this leads to reduced energy intake and gradual weight loss. The effect develops over time and depends on the dose.
Approved uses differ. In the UK, Ozempic is licensed for treating type 2 diabetes. Wegovy contains the same active ingredient but in a different dosing schedule and is licensed for weight management in people living with obesity, or with overweight and weight-related health conditions. The overall safety profile of semaglutide is similar across indications. Because doses differ, the frequency of certain side effects, especially gastrointestinal ones, may vary. Treatment should always follow approved dosing and be monitored by a doctor.
Dosing and how GLP-1 treatment is given
When starting Ozempic or Wegovy, the dose is adjusted individually to reduce the risk of side effects and support the best possible results. Treatment usually begins at a low dose, which is increased gradually if needed, following your doctor’s advice. This slow increase gives your body time to adjust and helps reduce unwanted symptoms.
Ozempic is given as a once-weekly injection under the skin, usually in the abdomen, thigh, or upper arm. It comes in a pre-filled injection pen designed to be simple to use at home after guidance from a doctor or nurse. It’s important to follow the instructions you’re given, as correct handling matters for both safety and effectiveness.
If you have questions about injections or notice side effects, you should contact your doctor. Regular follow-up and open communication help ensure treatment stays as safe and effective as possible.
What are the most common side effects?
Like all medicines, Ozempic and Wegovy can cause side effects. The most common ones affect the digestive system and are linked to how the medication works. Because semaglutide affects appetite signals and stomach emptying, temporary stomach symptoms can occur, especially at the start of treatment.
The most common side effects are:
- Nausea
- Diarrhoea
- Constipation
- Vomiting
- Wind and bloating
These symptoms are usually mild to moderate and most often appear when starting treatment or increasing the dose. For most people, they ease over time as the body adjusts.
How often and how strongly side effects are felt varies between individuals. Dose level, speed of dose increases, and personal factors all play a role. That’s why gradual dose increases and medical follow-up are important parts of treatment.
Are there other side effects linked to weight loss or GLP-1 treatment?
GLP-1 receptor agonists have been used in clinical practice for many years, so there is substantial knowledge about both short- and long-term effects. Research is still ongoing.
It’s important to separate symptoms directly linked to the medication from those related to weight loss itself. Because GLP-1 medicines often lead to reduced calorie intake and significant weight loss, effects linked to calorie deficit or rapid weight loss can become more noticeable. These may include gallstones, temporary hair thinning, and reduction in fat-free mass, including muscle.
There are also side effects that relate directly to the medication.
Below are examples of conditions that can occur in connection with weight loss and or GLP-1 treatment.
Loss of muscle mass during weight loss
When you lose weight, both fat mass and fat-free mass, including muscle, decrease. This happens whether weight loss comes from diet changes, medication, or bariatric surgery. The proportion of muscle lost varies and is influenced by calorie deficit, protein intake, physical activity, and body composition.
To help reduce unwanted muscle loss, the following are recommended:
- Adequate protein intake, tailored to individual needs
- Regular strength training
- Staying physically active in daily life
A structured plan that combines medication with nutrition guidance and exercise support can help improve body composition over time.
Temporary hair thinning during weight loss
Temporary hair thinning can happen with rapid weight loss or a clear calorie deficit. This is usually not caused by the medication itself, but by the body responding to changes in energy balance.
After significant weight loss, more hair follicles can shift into a resting phase, known as telogen effluvium. Hair shedding often becomes noticeable 2 to 4 months after the trigger.
For most people, this is temporary, and hair growth gradually recovers as the body adjusts.
Gallstones with rapid weight loss
Rapid and significant weight loss, regardless of method, is associated with an increased risk of gallstones. This also applies during treatment with semaglutide or other medications that lead to substantial weight reduction. The risk is mainly linked to the speed of weight loss rather than a direct effect of the medicine.
Typical symptoms of gallstones may include:
- Sudden pain under the right ribcage
- Pain spreading to the back or right shoulder
- Nausea, sometimes with fever
The overall risk is relatively low, but if you experience these symptoms, you should seek medical assessment.
Pancreatitis
Rare cases of pancreatitis have been reported during treatment with GLP-1 medicines.
Typical symptoms include:
- Severe and persistent pain in the upper abdomen
- Pain that may spread to the back
- Nausea and vomiting
This is uncommon but serious. If suspected, treatment should be stopped and urgent medical care sought.
Low blood sugar
Semaglutide on its own rarely causes low blood sugar. The risk increases in people with type 2 diabetes if it is combined with insulin or sulfonylureas. The risk of hypoglycaemia can be reduced by lowering the dose of insulin or sulfonylurea when starting a GLP-1 receptor agonist, under medical supervision.
How is treatment made safe?
Safety with GLP-1 treatment depends not only on the medicine, but on how it is started, adjusted, and monitored. A structured medical process is key to reducing risk and supporting long-term safety and effectiveness.
At Yazen, treatment is based on individual assessment and ongoing follow-up:
- Slow dose increases
Treatment always starts at a low dose and increases gradually if needed. The aim is to reach the desired effect at the lowest effective dose, which helps improve tolerance and reduce side effects. - Regular follow-up
Through digital tools and chat, the care team is available for ongoing support. If needed, the dose or treatment plan is adjusted. - Medical assessment
Before starting treatment, an individual medical review is carried out. Blood tests such as glucose levels, blood lipids, and liver markers are taken to understand your starting point and identify possible risk factors. Follow-up tests help monitor effectiveness and safety over time.
Read more about how Yazen works with medical weight management.
Lifestyle recommendations
For the best possible results with Ozempic or Wegovy, medication should be combined with healthy lifestyle habits. Treatment works best as part of a long-term, structured plan.
Nutrition
A balanced, nutrient-rich diet supports both weight loss and side effect management. Adequate protein intake is especially important to help preserve muscle during weight loss.
A well-composed diet may include:
- Protein-rich foods such as fish, eggs, and chicken
- Pulses and wholegrains
- Vegetables, fruit, and berries in a range of colours
If you feel nauseous, smaller and more frequent meals may be easier to manage. Some people also find it helpful to reduce fatty and very energy-dense foods, as fat slows stomach emptying and can worsen discomfort.
Physical activity and strength training
Regular physical activity increases energy expenditure, improves metabolic health, and supports overall wellbeing. Walking, cycling, or other aerobic exercise can complement treatment.
Strength training is particularly valuable during weight loss because it:
- Helps preserve muscle mass
- Supports metabolism
- Improves function, balance, and quality of life
Training larger muscle groups 2 to 3 times per week is recommended. Exercises for legs, back, chest, and core can be adapted to suit your level and circumstances.
At Yazen, you receive support from a doctor and a coach to create a plan tailored to your needs and goals. Everyone’s journey is different. That’s why it’s important to discuss lifestyle choices and challenges with your care team, so you can find a strategy that works for you long term.
Ozempic, weight loss and type 2 diabetes – what should you keep in mind?
Ozempic is not a quick fix. It’s part of a long-term medical strategy. To achieve sustainable results and maintain safety, it needs to be combined with lifestyle changes and structured follow-up.
GLP-1 receptor agonists such as Ozempic and Wegovy can support significant weight loss when used alongside lifestyle changes. Both contain semaglutide and are given as a once-weekly injection under the skin. They work by affecting appetite regulation, satiety, and blood sugar control.
It’s important to distinguish between approved uses. In the UK, Ozempic is licensed for type 2 diabetes. Wegovy is licensed for weight management in people living with obesity, or with overweight and related health conditions.
Most people do not experience serious complications. The most common side effects are gastrointestinal and tend to occur early in treatment or during dose increases. For most, these symptoms ease over time.
When treatment takes place under medical supervision, the overall balance of benefits and risks is favourable for many people. This is particularly relevant as both obesity and type 2 diabetes are linked to significant long-term health risks, including cardiovascular disease and metabolic complications.
If you experience new, severe, or persistent symptoms, you should contact your doctor for assessment.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). The New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). The New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2307563
- European Medicines Agency (EMA). Ozempic (semaglutide) – EPAR Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic
- European Medicines Agency (EMA). Wegovy (semaglutide) – EPAR Product Information. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
- Prado CM et al. Muscle matters: the effects of medically induced weight loss on skeletal muscle. The Lancet Diabetes & Endocrinology. https://pubmed.ncbi.nlm.nih.gov/39265590/
- Conte C et al. Is weight loss–induced muscle mass loss clinically relevant? JAMA. https://pubmed.ncbi.nlm.nih.gov/38829659/
- Linge J et al. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation. https://pubmed.ncbi.nlm.nih.gov/39401279/
- Postgraduate Medicine. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. https://www.tandfonline.com/doi/full/10.1080/00325481.2021.2002616
- Journal of Clinical Medicine. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists: A Multidisciplinary Expert Consensus. https://pmc.ncbi.nlm.nih.gov/articles/PMC9821052/#jcm-12-00145-t002
February 17, 2026
March 17, 2026
More articles
Diabetes medicines, weight loss and long-term health
Searches for diabetes medicines and weight loss have risen sharply. Lots of people want to understand the connection and who this kind of treatment might be right for. Some medicines originally developed for type 2 diabetes can also lead to weight loss. In this article, we explain how diabetes medicines and weight loss are linked, and which treatments may help support weight loss.
